HK Stock MarketDetailed Quotes

BAO PHARMA-B (02659)

Watchlist
  • 23.660
  • -0.880-3.59%
Trading Jun 1 11:39 CST
7.71BMarket Cap-17.62P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

BAO PHARMA-B (02659) Income Statement

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q6)Jun 30, 2025
(FY)Dec 31, 2024
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
Turnover
697.99%49.16M
2,716.23%41.99M
-11.11%6.16M
-11.94%4.44M
--1.49M
--6.93M
--5.04M
Operating income
697.99%49.16M
2,716.23%41.99M
-11.11%6.16M
-11.94%4.44M
1.49M
6.93M
5.04M
Cost of sales
-374.12%-5.41M
41.24%-265K
-665.10%-1.14M
-325.50%-634K
---451K
---149K
---149K
Operating expenses
-374.12%-5.41M
41.24%-265K
-665.10%-1.14M
-325.50%-634K
-451K
-149K
-149K
Gross profit
771.53%43.75M
3,912.02%41.73M
-25.97%5.02M
-22.21%3.81M
1.04M
6.78M
4.89M
Administrative expenses
2.81%-104.62M
6.21%-46.15M
-132.22%-107.64M
-130.33%-78.05M
---49.21M
---46.35M
---33.89M
Research and development expenses
0.99%-248.24M
4.51%-111.05M
-89.16%-250.73M
-91.51%-183.66M
---116.29M
---132.55M
---95.9M
Special items of operating profit
-1,244.70%-79.98M
-10,600.17%-64.84M
-136.52%-5.95M
-110.14%-1.58M
---606K
--16.29M
--15.56M
Operating profit
-8.29%-389.09M
-9.24%-180.32M
-130.57%-359.29M
-137.33%-259.48M
-165.07M
-155.83M
-109.34M
Financing cost
-31.12%-5.97M
-32.90%-2.67M
-24.65%-4.56M
-11.39%-3.22M
---2.01M
---3.66M
---2.89M
Share of profits of associates
60.92%-238K
52.50%-114K
33.44%-609K
35.79%-488K
---240K
---915K
---760K
Earning before tax
-8.46%-395.3M
-9.43%-183.1M
-127.22%-364.46M
-132.94%-263.19M
-167.31M
-160.4M
-112.98M
Tax
----
----
2,200.00%23K
195.83%23K
--23K
--1K
---24K
After-tax profit from continuing operations
-8.47%-395.3M
-9.45%-183.1M
-127.21%-364.43M
-132.87%-263.16M
-167.29M
-160.4M
-113.01M
Earning after tax
-8.47%-395.3M
-9.45%-183.1M
-127.21%-364.43M
-132.87%-263.16M
-167.29M
-160.4M
-113.01M
Profit attributable to shareholders
-8.47%-395.3M
-9.45%-183.1M
-127.21%-364.43M
-132.87%-263.16M
-167.29M
-160.4M
-113.01M
Basic earnings per share
0.00%-1.36
0.93%-3.18
57.10%-1.36
-122.12%-5.02
-3.21
-3.17
-2.26
Diluted earnings per share
0.00%-1.36
0.93%-3.18
57.10%-1.36
-122.12%-5.02
-3.21
-3.17
-2.26
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
IAS
IAS
IAS
IAS
IAS
IAS
IAS
Audit Opinions
Unqualified Opinion
--
Unqualified Opinion
--
--
Unqualified Opinion
--
Auditor
Ernst & Young
--
Ernst & Young
--
--
Ernst & Young
--
(FY)Dec 31, 2025(Q6)Jun 30, 2025(FY)Dec 31, 2024(Q9)Sep 30, 2024(Q6)Jun 30, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023
Turnover 697.99%49.16M2,716.23%41.99M-11.11%6.16M-11.94%4.44M--1.49M--6.93M--5.04M
Operating income 697.99%49.16M2,716.23%41.99M-11.11%6.16M-11.94%4.44M1.49M6.93M5.04M
Cost of sales -374.12%-5.41M41.24%-265K-665.10%-1.14M-325.50%-634K---451K---149K---149K
Operating expenses -374.12%-5.41M41.24%-265K-665.10%-1.14M-325.50%-634K-451K-149K-149K
Gross profit 771.53%43.75M3,912.02%41.73M-25.97%5.02M-22.21%3.81M1.04M6.78M4.89M
Administrative expenses 2.81%-104.62M6.21%-46.15M-132.22%-107.64M-130.33%-78.05M---49.21M---46.35M---33.89M
Research and development expenses 0.99%-248.24M4.51%-111.05M-89.16%-250.73M-91.51%-183.66M---116.29M---132.55M---95.9M
Special items of operating profit -1,244.70%-79.98M-10,600.17%-64.84M-136.52%-5.95M-110.14%-1.58M---606K--16.29M--15.56M
Operating profit -8.29%-389.09M-9.24%-180.32M-130.57%-359.29M-137.33%-259.48M-165.07M-155.83M-109.34M
Financing cost -31.12%-5.97M-32.90%-2.67M-24.65%-4.56M-11.39%-3.22M---2.01M---3.66M---2.89M
Share of profits of associates 60.92%-238K52.50%-114K33.44%-609K35.79%-488K---240K---915K---760K
Earning before tax -8.46%-395.3M-9.43%-183.1M-127.22%-364.46M-132.94%-263.19M-167.31M-160.4M-112.98M
Tax --------2,200.00%23K195.83%23K--23K--1K---24K
After-tax profit from continuing operations -8.47%-395.3M-9.45%-183.1M-127.21%-364.43M-132.87%-263.16M-167.29M-160.4M-113.01M
Earning after tax -8.47%-395.3M-9.45%-183.1M-127.21%-364.43M-132.87%-263.16M-167.29M-160.4M-113.01M
Profit attributable to shareholders -8.47%-395.3M-9.45%-183.1M-127.21%-364.43M-132.87%-263.16M-167.29M-160.4M-113.01M
Basic earnings per share 0.00%-1.360.93%-3.1857.10%-1.36-122.12%-5.02-3.21-3.17-2.26
Diluted earnings per share 0.00%-1.360.93%-3.1857.10%-1.36-122.12%-5.02-3.21-3.17-2.26
Currency Unit CNYCNYCNYCNYCNYCNYCNY
Accounting Standards IASIASIASIASIASIASIAS
Audit Opinions Unqualified Opinion--Unqualified Opinion----Unqualified Opinion--
Auditor Ernst & Young--Ernst & Young----Ernst & Young--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 0.00%
Sample Name
Sample Code
 -2.73%
Sample Name
Sample Code
 -5.86%
4
CNOOC
00883
-8.10%
5
PETROCHINA
00857
-8.23%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +28.66%
Sample Name
Sample Code
 +19.86%
Sample Name
Sample Code
 +7.44%
4
Thunder Software Technology
300496
+3.65%
5
China Greatwall Technology Group
000066
+2.61%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -